MedPath

Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

Phase 3
Active, not recruiting
Conditions
Myelofibrosis (MF)
Interventions
Registration Number
NCT04472598
Lead Sponsor
AbbVie
Brief Summary

Myelofibrosis is a type of bone marrow cancer that usually develops slowly and disrupts body's normal production of blood cells. It causes bone marrow scarring, leading to severe anemia that can cause weakness and fatigue. It can also cause a low number of blood-clotting cells called platelets, which increases risk of bleeding. Myelofibrosis often causes an enlarged spleen. The purpose of this study is to see if a combination of navitoclax and ruxolitinib is more effective and safe in assessment of change in spleen volume when compared to ruxolitinib in participants with myelofibrosis.

Navitoclax is an investigational drug for the treatment of myelofibrosis. Participants in this study are divided into two groups, called treatment arms. Each group receives a different treatment. Adult participants with a diagnosis of myelofibrosis will be enrolled. Around 230 participants will be enrolled in approximately 190 sites worldwide.

Participants will receive oral navitoclax tablet with oral ruxolitinib tablet or oral ruxolitinib tablet with oral placebo (no active drug) tablet and treatment may continue untill the participant cannot tolerate the study drug, or benefit is not achieved, or other reasons which qualify for discontinuation of the study drug.

There may be a higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, magnetic resonance imaging (MRI) or computed tomography (CT) scan, bone marrow tests, checking for side effects, and completing questionnaires.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
252
Inclusion Criteria
  • Documented diagnosis of Primary MyeloFibrosis (MF) as defined by World Health Organization (WHO) classification or Secondary MF (post polycythemia vera [PPV] - MF or Post Essential Thrombocytopenia [PET] - MF) .

  • Must be able to complete the MF Symptom Assessment Form (MFSAF) v4.0 on at least 4 out of 7 days immediately preceding the date of randomization.

    -- Must have at least 2 symptoms with a score >=3 or a total score of >=12, as measured by the MFSAF v4.0.

  • Classified as intermediate-2, or high-Risk MF as defined by the Dynamic International Prognostic Scoring System Plus (DIPSS+).

  • Has splenomegaly defined as spleen palpation measurement >= 5 centimeters (cm) below costal margin or spleen volume greater than or equal to 450 cubic cm as assessed centrally by magnetic resonance imaging (MRI) or computed tomography (CT) scan.

  • Ineligible for stem cell transplantation at time of study entry due to age, comorbidities, or unfit for unrelated or unmatched donor transplant and other criteria per National Comprehensive Cancer Network guidelines.

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

Read More
Exclusion Criteria
  • Prior treatment with a Janus Kinase-2 (JAK-2) inhibitor.
  • Prior treatment with a B-cell lymphoma 2 homology 3 (BH3)-mimetic compound or bromodomain and extra-terminal motif (BET) inhibitor or stem cell transplant.
  • Receiving medication that interferes with coagulation or platelet function within 3 days prior to the first dose of study drug or during the study treatment period except for low dose aspirin (up to 100 milligram daily) and low molecular weight heparin (LMWH).
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Placebo for Navitoclax + RuxolitinibPlacebo for NavitoclaxParticipants will receive placebo for Navitoclax and Ruxolitinib
Navitoclax + RuxolitinibRuxolitinibParticipants will receive Navitoclax in combination with Ruxolitinib
Placebo for Navitoclax + RuxolitinibRuxolitinibParticipants will receive placebo for Navitoclax and Ruxolitinib
Navitoclax + RuxolitinibNavitoclaxParticipants will receive Navitoclax in combination with Ruxolitinib
Primary Outcome Measures
NameTimeMethod
Percentage of Participants who achieve Spleen Volume Reduction of at least 35% at Week 24 (SVR35W24)At Week 24

Reduction in spleen volume is measured by magnetic resonance imaging (MRI) or computed tomography (CT), per International Working Group (IWG) criteria.

Secondary Outcome Measures
NameTimeMethod
Duration of 35% Spleen Volume Reduction (SVR35)Baseline (Week 0) Up to Week 96

Duration of SVR35 is defined as the time between the date of first response of spleen volume reduction of 35% achievement to the date of the first assessment where the spleen volume is less than 35% reduction from baseline and is at least 25% increase from the nadir (the lowest spleen volume).

Change in Physical FunctioningBaseline (Week 0) Up to Week 24

Change in physical functioning is measured by the physical functioning domain of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 or death.

Percentage of Participants who achieve Anemia ResponseBaseline (Week 0) Up to Week 96

The rate of anemia response will be assessed according to current International Working Group-Myeloproliferative Neoplasms Research and European LeukemiaNet (IWG-MRT/ELN) criteria.

Change in Total Symptom Score (TSS)Baseline (Week 0) Up to Week 24

Reduction in TSS is measured by Myelofibrosis Symptom Assessment Form (MFSAF) v4.0.

Percentage of Participants who achieve Spleen Volume Reduction of at least 35% (SVR35)Baseline (Week 0) Up to Week 96

Reduction in spleen volume is measured by MRI or CT, per IWG criteria.

Change In FatigueBaseline (Week 0) Up to Week 24

Change in fatigue will be assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue SF 7a.

Overall Survival (OS)Up To approximately 8 Years

OS is defined as the time from the date of randomization to the date of death from any cause.

Leukemia-Free SurvivalUp To approximately 8 Years

Leukemia-free survival is defined as the number of days from the date of randomization to the onset date of documented leukemia, disease progression due to leukemia, or death due to leukemia, whichever occurs first.

Percentage of Participants who Achieve Reduction in Grade of Bone Marrow FibrosisBaseline (Week 0) Up to Week 96

Change in grade of bone marrow fibrosis will be measured per the European consensus grading system through bone marrow biopsy.

Trial Locations

Locations (194)

Lakeridge Health - Oshawa /ID# 222080

🇨🇦

Oshawa, Ontario, Canada

Indiana Blood & Marrow Transpl /ID# 221586

🇺🇸

Indianapolis, Indiana, United States

University of Texas MD Anderson Cancer Center /ID# 217994

🇺🇸

Houston, Texas, United States

Royal Perth Hospital /ID# 223203

🇦🇺

Perth, Western Australia, Australia

CHU UCL Namur - site Godinne /ID# 221127

🇧🇪

Godinne, Namur, Belgium

Rocky Mountain Cancer Centers, LLP- Littleton /ID# 222562

🇺🇸

Littleton, Colorado, United States

Minnesota Oncology Hematology /ID# 227357

🇺🇸

Edina, Minnesota, United States

Oncology Hematology Care, Inc. /ID# 222556

🇺🇸

Cincinnati, Ohio, United States

Chu Angers /Id# 219115

🇫🇷

Angers, France

Moores Cancer Center at UC San Diego /ID# 218012

🇺🇸

La Jolla, California, United States

Providence Medical Foundation /ID# 241646

🇺🇸

Fullerton, California, United States

Emory University /ID# 221562

🇺🇸

Atlanta, Georgia, United States

Florida Cancer Specialist - South /ID# 221726

🇺🇸

Fort Myers, Florida, United States

Florida Cancer Specialists - East /ID# 221728

🇺🇸

West Palm Beach, Florida, United States

Columbus Regional Research Institute /ID# 227272

🇺🇸

Columbus, Georgia, United States

Rush University Medical Center /ID# 221581

🇺🇸

Chicago, Illinois, United States

Mid Illinois Hematology & Oncology Associates, Ltd /ID# 224204

🇺🇸

Normal, Illinois, United States

University of Kansas Cancer Center /ID# 218144

🇺🇸

Fairway, Kansas, United States

Hackensack Univ Med Ctr /ID# 221654

🇺🇸

Hackensack, New Jersey, United States

Weill Cornell Medical College /ID# 220933

🇺🇸

New York, New York, United States

Northwell Health - Monter Cancer Center /ID# 222996

🇺🇸

Lake Success, New York, United States

Gabrail Cancer Center Research /ID# 230488

🇺🇸

Canton, Ohio, United States

Thompson Cancer Survival Ctr /ID# 231689

🇺🇸

Knoxville, Tennessee, United States

The Ohio State University /ID# 221584

🇺🇸

Columbus, Ohio, United States

UPMC Hillman Cancer Ctr /ID# 218134

🇺🇸

Pittsburgh, Pennsylvania, United States

Virginia Cancer Specialists - Fairfax /ID# 242682

🇺🇸

Fairfax, Virginia, United States

University of Utah /ID# 221009

🇺🇸

Salt Lake City, Utah, United States

Texas Oncology - Northeast Texas /ID# 241813

🇺🇸

Tyler, Texas, United States

Utah Cancer Specialists Salt Lake Clinic /ID# 221961

🇺🇸

Salt Lake City, Utah, United States

Border Medical Oncology Research Unit Albury Wodonga Regional Cancer Centre /ID# 231311

🇦🇺

East Albury, New South Wales, Australia

VA Puget Sound Health Care System /ID# 231691

🇺🇸

Seattle, Washington, United States

The Kinghorn Cancer Centre /ID# 221503

🇦🇺

Darlinghurst, New South Wales, Australia

Gosford Hospital /ID# 221499

🇦🇺

Gosford, New South Wales, Australia

Liverpool Hospital /ID# 221803

🇦🇺

Liverpool, New South Wales, Australia

Peter MacCallum Cancer Ctr /ID# 229795

🇦🇺

Melbourne, Victoria, Australia

Alfred Health /ID# 221501

🇦🇺

Melbourne, Victoria, Australia

Townsville University Hospital /ID# 229794

🇦🇺

Douglas, Queensland, Australia

Klinikum Wels-Grieskirchen GmbH /ID# 220901

🇦🇹

Wels, Oberoesterreich, Austria

Medizinische Universitaet Wien /ID# 220906

🇦🇹

Vienna, Wien, Austria

UZ Gent /ID# 221125

🇧🇪

Gent, Oost-Vlaanderen, Belgium

Medizinische Universitaet Graz /ID# 220910

🇦🇹

Graz, Steiermark, Austria

Hanusch Krankenhaus /ID# 220909

🇦🇹

Wien, Austria

Universitair Ziekenhuis Leuven /ID# 218806

🇧🇪

Leuven, Vlaams-Brabant, Belgium

Vitaz /Id# 229861

🇧🇪

Sint-Niklaas, Belgium

ZNA Stuivenberg /ID# 221465

🇧🇪

Antwerp, Belgium

AZ Sint-Jan Brugge /ID# 218805

🇧🇪

Brugge, Belgium

Centre Hospitalier Universitaire du Sart Tilman CHU de Liege /ID# 218874

🇧🇪

Liege, Belgium

UMHAT Alexandrovska EAD /ID# 231056

🇧🇬

Sofiya, Sofia, Bulgaria

AZ-Delta /ID# 221466

🇧🇪

Roeselare, West-Vlaanderen, Belgium

UMHAT Dr Georgi Stranski EAD /ID# 231161

🇧🇬

Pleven, Bulgaria

UMHAT Sveti Georgi /ID# 231053

🇧🇬

Plovdiv, Bulgaria

Acibadem City Clinic Tokuda University Hospital EAD /ID# 231036

🇧🇬

Sofia, Bulgaria

UMHAT Sveti Ivan Rilski /ID# 231028

🇧🇬

Sofia, Bulgaria

Royal Victoria Hospital /ID# 222636

🇨🇦

Barrie, Ontario, Canada

Juravinski Cancer Centre /ID# 221752

🇨🇦

Hamilton, Ontario, Canada

Niagara Health System /ID# 230994

🇨🇦

St Catharines, Ontario, Canada

CHUQ- Hôpital de l'Enfant-Jesus /ID# 221754

🇨🇦

Quebec City, Quebec, Canada

Klinicki bolnicki centar Zagreb /ID# 230793

🇭🇷

Zagreb, Grad Zagreb, Croatia

Klinicka bolnica Merkur /ID# 231155

🇭🇷

Zagreb, Grad Zagreb, Croatia

HCL - Hopital Lyon Sud /ID# 222913

🇫🇷

Pierre Benite CEDEX, Auvergne-Rhone-Alpes, France

Klinicki bolnicki centar Split /ID# 230796

🇭🇷

Split, Splitsko-dalmatinska Zupanija, Croatia

CHU NIMES - Hopital Caremeau /ID# 219114

🇫🇷

Nimes CEDEX 9, Gard, France

CHU Bordeaux - Hopital Haut Leveque /ID# 222518

🇫🇷

Pessac, Gironde, France

CH Roubaix - Hopital Victor Provo /ID# 219116

🇫🇷

Roubaix Cedex 1, Hauts-de-France, France

Hopital Avicenne - APHP /ID# 221286

🇫🇷

Bobigny, Ile-de-France, France

AP-HP - Hopital Necker /ID# 231318

🇫🇷

Paris, France

Centre Hospitalier de CHAMBERY /ID# 224506

🇫🇷

Chambery, Savoie, France

ICANS - Institut de Cancérologie Strasbourg Europe /ID# 229978

🇫🇷

Strasbourg Cedex, France

AP-HP - Hopital Saint-Louis /ID# 221288

🇫🇷

Paris, France

OncoResearch Lerchenfeld GmbH /ID# 230867

🇩🇪

Hamburg, Germany

Universitaetsklinikum Aachen /ID# 221519

🇩🇪

Aachen, Nordrhein-Westfalen, Germany

BAG Freiberg-Richter, Jacobasch, Illmer, Wolf /ID# 221347

🇩🇪

Dresden, Sachsen, Germany

Universitaetsklinikum Essen /ID# 221522

🇩🇪

Essen, Germany

Klinikum rechts der Isar - Technische Universitaet Muenchen /ID# 221520

🇩🇪

Munich, Germany

University General Hospital Attikon /ID# 230784

🇬🇷

Athens, Attiki, Greece

General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 230786

🇬🇷

Athens, Greece

The Chaim Sheba Medical Center /ID# 219137

🇮🇱

Ramat Gan, Tel-Aviv, Israel

Hadassah Medical Center-Hebrew University /ID# 219110

🇮🇱

Jerusalem, Yerushalayim, Israel

Rambam Health Care Campus /ID# 219120

🇮🇱

Haifa, Israel

Assaf Harofeh Medical Center /ID# 222957

🇮🇱

Be'Er Ya'Akov, Israel

Meir Medical Center /ID# 221374

🇮🇱

Kfar Saba, Israel

ASST Spedali civili di Brescia /ID# 241273

🇮🇹

Brescia, Italy

Azienda Ospedaliero Universitaria Careggi /ID# 219086

🇮🇹

Florence, Italy

Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni /ID# 221907

🇮🇹

Bergamo, Italy

IRCCS Azienda Ospedaliero-Universitaria di Bologna /ID# 220867

🇮🇹

Bologna, Italy

A.O.U. Policlinico G. Rodolico S.Marco- Presidio G.Rodolico /ID# 219085

🇮🇹

Catania, Italy

Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital /ID# 239100

🇯🇵

Nagoya-shi, Aichi, Japan

ASST Sette Laghi /ID# 219084

🇮🇹

Varese, Italy

Fujita Health University Hospital /ID# 221537

🇯🇵

Toyoake-shi, Aichi, Japan

Chiba University Hospital /ID# 239345

🇯🇵

Chiba-shi, Chiba, Japan

Ehime University Hospital /ID# 221443

🇯🇵

Toon-shi, Ehime, Japan

National Cancer Center Hospital East /ID# 226093

🇯🇵

Kashiwa-shi, Chiba, Japan

Kyushu University Hospital /ID# 221783

🇯🇵

Fukuoka-shi, Fukuoka, Japan

Fukushima Medical University Hospital /ID# 222752

🇯🇵

Fukushima-shi, Fukushima, Japan

Ogaki Municipal Hospital /ID# 240173

🇯🇵

Ogaki-shi, Gifu, Japan

Gunma University Hospital /ID# 221480

🇯🇵

Maebashi-shi, Gunma, Japan

Gunmaken Saiseikai Maebashi Hospital /ID# 242806

🇯🇵

Maebashi-shi, Gunma, Japan

Hokkaido University Hospital /ID# 242667

🇯🇵

Sapporo-shi, Hokkaido, Japan

Hitachi General Hospital /ID# 240048

🇯🇵

Hitachi-shi, Ibaraki, Japan

Medical Corporation Seijinkai Ikeda Hospital /ID# 242172

🇯🇵

Kanoya-shi, Kagoshima, Japan

Kobe University Hospital /ID# 246236

🇯🇵

Kobe-shi, Hyogo, Japan

Kanazawa University Hospital /ID# 238424

🇯🇵

Kanazawa-shi, Ishikawa, Japan

Kyoto University Hospital /ID# 238423

🇯🇵

Kyoto-shi, Kyoto, Japan

University of Miyazaki Hospital /ID# 221483

🇯🇵

Miyazaki-shi, Miyazaki, Japan

Kawasaki Medical School Hospital /ID# 221481

🇯🇵

Kurashiki-shi, Okayama, Japan

Kurashiki Central Hospital /ID# 221692

🇯🇵

Kurashiki-shi, Okayama, Japan

Kansai Medical University Hospital /ID# 221482

🇯🇵

Hirakata-shi, Osaka, Japan

Kindai University Hospital /ID# 221479

🇯🇵

Osakasayama-shi, Osaka, Japan

Osaka University Hospital /ID# 221478

🇯🇵

Suita-shi, Osaka, Japan

Dokkyo Medical University Saitama Medical Center /ID# 222333

🇯🇵

Koshigaya-shi, Saitama, Japan

Juntendo University Hospital /ID# 221405

🇯🇵

Bunkyo-ku, Tokyo, Japan

Nippon Medical School Hospital /ID# 221674

🇯🇵

Bunkyo-ku, Tokyo, Japan

Inje University Busan Paik Hospital /ID# 231667

🇰🇷

Busan, Korea, Republic of

Seoul National University Bundang Hospital /ID# 219053

🇰🇷

Seongnam, Gyeonggido, Korea, Republic of

Gachon University Gil Medical Center /ID# 222089

🇰🇷

Incheon, Korea, Republic of

Kyungpook National University Hospital /ID# 231666

🇰🇷

Daegu, Korea, Republic of

Seoul National University Hospital /ID# 219055

🇰🇷

Seoul, Korea, Republic of

Asan Medical Center /ID# 219054

🇰🇷

Seoul, Korea, Republic of

Middlemore Clinical Trials /ID# 230770

🇳🇿

Papatoetoe, Auckland, New Zealand

Radboud Universitair Medisch Centrum /ID# 218948

🇳🇱

Nijmegen, Gelderland, Netherlands

Samsung Medical Center /ID# 221068

🇰🇷

Seoul, Korea, Republic of

The Catholic University of Korea, Seoul St. Mary's Hospital /ID# 219056

🇰🇷

Seoul, Korea, Republic of

Albert Schweitzer Ziekenhuis /ID# 224015

🇳🇱

Dordrecht, Zuid-Holland, Netherlands

Universitair Medisch Centrum Groningen /ID# 218947

🇳🇱

Groningen, Netherlands

Universitair Medisch Centrum Utrecht /ID# 218949

🇳🇱

Utrecht, Netherlands

Moscow State budget healthcare /ID# 221025

🇷🇺

Moscow, Moskva, Russian Federation

University Clinical Center Serbia /ID# 230854

🇷🇸

Belgrade, Beograd, Serbia

Leningrad Regional Clinical Hospital /ID# 221028

🇷🇺

Saint Petersburg, Russian Federation

Clinical Center Vojvodina /ID# 230853

🇷🇸

Novi Sad, Vojvodina, Serbia

University Clinical Center Kragujevac /ID# 230855

🇷🇸

Kragujevac, Sumadijski Okrug, Serbia

Wits Clinical Research Site /ID# 232072

🇿🇦

Johannesburg, Gauteng, South Africa

Clin Hosp Ctr Bezanijska Kosa /ID# 230946

🇷🇸

Belgrade, Beograd, Serbia

Albert Alberts Stem Cell Transplant Centre /ID# 232073

🇿🇦

Pretoria, Gauteng, South Africa

Hospital Universitario Vall d'Hebron /ID# 229690

🇪🇸

Barcelona, Spain

Hospital Parc de Salut del Mar /ID# 220913

🇪🇸

Barcelona, Spain

Hospital Clínico Universitario de Santiago-CHUS /ID# 222264

🇪🇸

Santiago de Compostela, A Coruna, Spain

Hospital Universitario Dr. Negrin /ID# 220897

🇪🇸

Las Palmas de Gran Canaria, Las Palmas, Spain

CLINICA UNIVERSIDAD DE NAVARRA-Pamplona /ID# 230720

🇪🇸

Pamplona, Navarra, Spain

CLINICA UNIVERSIDAD DE NAVARRA-Madrid /ID# 230721

🇪🇸

Madrid, Spain

Hospital Universitario Virgen de la Victoria /ID# 220878

🇪🇸

Malaga, Spain

Hospital Universitario 12 de Octubre /ID# 229691

🇪🇸

Madrid, Spain

Hospital Universitario Ramon y Cajal /ID# 220877

🇪🇸

Madrid, Spain

Hospital Clinico Universitario de Valencia /ID# 220875

🇪🇸

Valencia, Spain

Orebro Universitetssjukhuset /ID# 220829

🇸🇪

Orebro, Orebro Lan, Sweden

National Taiwan University Hospital /ID# 218976

🇨🇳

Taipei City, Taiwan

China Medical University Hospital /ID# 218978

🇨🇳

Taichung City, Taiwan

Skane University Hospital Lund /ID# 220835

🇸🇪

Lund, Skane Lan, Sweden

Sahlgrenska University Hospital /ID# 218776

🇸🇪

Gothenburg, Vastra Gotalands Lan, Sweden

Chi Mei Hospital - Liouying /ID# 221145

🇨🇳

Tainan City, Taiwan

Linkou Chang Gung Memorial Hospital /ID# 218983

🇨🇳

Taoyuan City, Taiwan

Bagcilar Medipol Mega Universite Hastanesi /ID# 230757

🇹🇷

Istanbul, Turkey

Taipei Veterans General Hosp /ID# 221146

🇨🇳

Taipei City, Taiwan

Trakya University Medical Facu /ID# 230754

🇹🇷

Edirne, Istanbul, Turkey

Hacettepe University Medical Faculty /ID# 230759

🇹🇷

Ankara, Turkey

Communal non-profit enterprise Regional Center of Oncology /ID# 230832

🇺🇦

Kharkiv, Ukraine

Inonu University Medical Faculty /ID# 230758

🇹🇷

Malatya, Turkey

Medical Center "OK!Clinic+" /ID# 230834

🇺🇦

Kyiv, Ukraine

Feofaniya Clinical Hospital of State Management of Affairs /ID# 232370

🇺🇦

Kyiv, Ukraine

SI Institute of Blood Pathology and Transfusion Medicine of NAMS of Ukraine /ID# 230833

🇺🇦

Lviv, Ukraine

United Lincolnshire Hospitals NHS Trust /ID# 231471

🇬🇧

Lincoln, Lincolnshire, United Kingdom

Oxford University Hospitals NHS Foundation Trust /ID# 219192

🇬🇧

Oxford, Oxfordshire, United Kingdom

Guys and St Thomas NHS Foundation Trust /ID# 219185

🇬🇧

London, London, City Of, United Kingdom

Augusta University Georgia Cancer Center /ID# 221551

🇺🇸

Augusta, Georgia, United States

Massachusetts General Hospital /ID# 221559

🇺🇸

Boston, Massachusetts, United States

Clinical Hospital Dubrava /ID# 230795

🇭🇷

Zagreb, Grad Zagreb, Croatia

Juntendo University Shizuoka Hospital /ID# 221782

🇯🇵

Izunokuni-shi, Shizuoka, Japan

Pusan National University Hospital /ID# 222087

🇰🇷

Busan, Korea, Republic of

Russian Research Institute of Hematology and Transfusiology of the FMBA /ID# 221029

🇷🇺

Sankt-Peterburg, Russian Federation

Republican hospital named after V.A. Baranov /ID# 221412

🇷🇺

Petrozavodsk, Russian Federation

Wits Clinical Research Site /ID# 232071

🇿🇦

Johannesburg, Gauteng, South Africa

Hospital Universitario Germans Trias i Pujol /ID# 229936

🇪🇸

Badalona, Barcelona, Spain

University Hospitals Birmingham NHS Foundation Trust /ID# 221333

🇬🇧

Birmingham, United Kingdom

The Christie Hospital /ID# 219191

🇬🇧

Manchester, United Kingdom

University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 221658

🇺🇸

Ann Arbor, Michigan, United States

Haemato-Onkologie /ID# 221061

🇩🇪

Muenchen, Bayern, Germany

Tel Aviv Sourasky Medical Center /ID# 219134

🇮🇱

Tel Aviv-Yafo, Tel-Aviv, Israel

Highlands Oncology Group, PA /ID# 221824

🇺🇸

Springdale, Arkansas, United States

Dana-Farber Cancer Institute /ID# 218010

🇺🇸

Boston, Massachusetts, United States

Lynn Cancer Institute, Boca /ID# 230687

🇺🇸

Boca Raton, Florida, United States

Clinic UZI 4D /ID# 221024

🇷🇺

Pyatigorsk, Stavropol Skiy Kray, Russian Federation

Tula Regional Clinical Hospital /ID# 221027

🇷🇺

Tula, Russian Federation

Beth Israel Deaconess Medical Center /ID# 224261

🇺🇸

Boston, Massachusetts, United States

Florida Cancer Specialists - North /ID# 221727

🇺🇸

Saint Petersburg, Florida, United States

Ordensklinikum Linz GmbH Elisabethinen /ID# 220813

🇦🇹

Linz, Oberoesterreich, Austria

University of Yamanashi Hospital /ID# 221701

🇯🇵

Chuo-shi, Yamanashi, Japan

Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 219083

🇮🇹

Rome, Lazio, Italy

Universitatsklinikum Mannheim /ID# 221523

🇩🇪

Mannheim, Baden-Wuerttemberg, Germany

General Hospital of Athens Laiko /ID# 230785

🇬🇷

Athens, Attiki, Greece

Almazov National Medical Research Centre /ID# 221033

🇷🇺

Sankt-Peterburg, Russian Federation

CHU de Nantes, Hotel Dieu -HME /ID# 219113

🇫🇷

Nantes, Pays-de-la-Loire, France

Mie University Hospital /ID# 221664

🇯🇵

Tsu-shi, Mie, Japan

Ege University Medical Faculty /ID# 230753

🇹🇷

Izmir, Turkey

Kaohsiung Chang Gung Memorial Hospital /ID# 218984

🇨🇳

Kaohsiung City, Kaohsiung, Taiwan

MidAmerica Division, Inc. /ID# 221743

🇺🇸

Kansas City, Missouri, United States

© Copyright 2025. All Rights Reserved by MedPath